Extended Data Fig. 7: Probability that the IXCHIQ vaccine benefits outweigh the risks of vaccine SAEs by age group and epidemiological scenario, assuming that 50% of medically attended CHIKV infections are equivalent in health burden to SAEs. | Nature Health

Extended Data Fig. 7: Probability that the IXCHIQ vaccine benefits outweigh the risks of vaccine SAEs by age group and epidemiological scenario, assuming that 50% of medically attended CHIKV infections are equivalent in health burden to SAEs.

From: A framework for risk–benefit analysis of vaccines approved through accelerated pathways

Extended Data Fig. 7: Probability that the IXCHIQ vaccine benefits outweigh the risks of vaccine SAEs by age group and epidemiological scenario, assuming that 50% of medically attended CHIKV infections are equivalent in health burden to SAEs.

Open diamonds show the evidence available at the end of the trial and solid circles show all evidence currently available. Vertical dashed line denotes 95% probability (n = 100,000 posterior samples). SAE: serious adverse event.

Back to article page